Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: Effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor

Learning and Memory

Volumn 7, Issue 3, 2000, Pages 159-169

  Marighetto, Aline ^a   Touzani, Khalid ^a   Etchamendy, Nicole ^a   Torrea, Cedric Cortes ^a   De Nanteuil, Guillaume ^b   Guez, David ^b   Jaffard, Robert ^a   Morain, Philippe ^b  

^a CNRS   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROLYL ENDOPEPTIDASE INHIBITOR; S 17092; TACRINE; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISCRIMINATION LEARNING; DRUG EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPONSE TIME; SPATIAL DISCRIMINATION; TASK PERFORMANCE;

AGING; ANIMALS; CHOICE BEHAVIOR; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DISCRIMINATION (PSYCHOLOGY); INDOLES; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; REACTION TIME; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; TACRINE; THIAZOLES; THIAZOLIDINES; TIME FACTORS;

EID: 0034051361     PISSN: 10720502     EISSN: None     Source Type: Journal    
DOI: 10.1101/lm.7.3.159     Document Type: Article

References (45)

1. Bartus, R.T., R.L. Dean, M.J. Pontecorco, and C. Flicker. 1985. The cholinergic hypothesis: A historical overview, current perspective, and future directions. Ann. NY Acad. Sci. 444: 332-358.
2. Beal, M.F. and M.F. Mazurek. 1987. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology 37: 1205-1209.
3. Bennett, G.W., T.M. Ballard, C.D. Watson, and K.C.F. Fone. 1997. Effects of neuropeptides on cognitive function. Exp. Gerontol. 32: 451-469.
4. Blokland, A. 1996. Acerylcholine: A neurotransmitter for learning and memory? Brain Res. Rev. 21: 285-300.
5. Buck, S. H., P.P. Deshmukh, T.F. Burks, and H.I. Yamamura. 1981. A survey of substance P, somastotatin, and neurotensin levels in aging in the rat and human central nervous system. Neurobiol. Aging 2: 257-264.
6. Cohen, N.J. 1984. Preserved learning capacity in amnesia: Evidence for multiple memory systems. In Neurospsychology of memory (ed. L.R. Squire and N. Butters), pp. 83-103. Guilford Press, New York, NY.
7. Coyle, J.T., D.I., Price, and M.R. DeLong. 1983. Alzheimer disease: A disorder of cortical cholinergic innervation. Science 219: 1184-1190.
8. Davies, P. and A.J.F. Maloney. 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403-1046.
9. Dekker, A., W.H. Gispen, and D. De Wied. 1987. Axonal regeneration, growth factors and neuropeptides. Life Sci. 41: 1667-1678.
10. Dupont, A., P. Savard, Y. Merand, F. Labrie, and J.R. Boissier. 1981. Age-related changes in central nervous system enkephalins and substance P. Life Sci. 29: 2317-2322.
11. Eichenbaum, H. 1992. The hippocampal system and declarative memory in animals. J. Cognitive Neurosci. 4: 217-231.
12. Eichenbaum, H., T. Otto, and N.J. Cohen. 1994. The hippocampus - What does it do? Behav. Neural Biol. 57: 2-36.
13. Flood, J.F. and A. Cherkin. 1988. Effect of acute arecoline, tacrine and arecoline+tacrine post-training administration on retention in old mice. Neurobiol. Aging 9: 5-8.
14. Ferrier, I.N., A.J. Cross, J.A. Johnson, G.W. Roberts, T.J. Crow, J.A. Corsellis, Y.C. Lee, D. O'Shaughnessy, T.E. Adrian, G.P. McGregor, et al. 1983. Neuropeptides in Alzheimer type dementia. J. Neurol. Sci. 62: 159-170.
15. Gabrieli, J.D.E. 1996. Memory systems analyses of mnemonic disorders in aging and age-related diseases. PNAS 93: 13534-13540.
16. Gallagher, M. and P.J. Colombo. 1995. Aging: the cholinergic hypothesis of cognitive decline. Curr. Opinion Neurobiol. 5: 161-168.
17. Giovannini, M.G., F. Casamenti, A. Nistri, F. Paoli, and G. Pepeu. 1991. Effect of thyrotropin releasing hormone (TRH) on acetylcholine release from different brain areas investigated by microdialysis. Br. J. Pharmacol. 102: 363-368.
18. Hasenöhrl, R.U., J.P. Huston, and T. Schuurman. 1990. Neuropeptide Subtance P improves water maze performance in aged rats. Psychopharmacol. 101: 23-26.
19. Husain, N.M. and C.B. Nemeroff. 1990. Neuropeptides and Alzheimer's disease. J. Am. Geriatr. Soc. 38: 918-925.
20. Itoh, J., T. Nabeshima, and T. Kameyama. 1990. Utility of an elevated plus-maze for the evaluation of memory in mice: Effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacol. 101: 27-33.
21. Iwasaki, Y., M. Kinoshita, K. Ikeda, K. Takamiya, T. Shiojima. 1989. Trophic effect of various neuropeptides on the cultured ventral spinal cord of rat embryo. Neurosci. Lett. 101: 316-320.
22. Kirkby, D.L., D.N.C. Jones, J.C. Barnes, and G.A. Higgins. 1996. Effects of anticholinesterase drugs tacrine and E2020, the 5HT3 antagonist ondansetron, and the H3 antagonist thioperamide, in models of cognition and cholinergic function. Behav. Pharmacol. 7: 513-525
23. Lépagnol, J., C. Lebrun, P. Morain, G. de Nanteuil, and V. Meidet. 1996. Cognition enhancing effects of S 17092, a potent and long acting inhibitor of post-proline cleaving enzyme (PPCE). Soc. Neurosci. Abst. 142.
24. Lestage, P., A. Iris-Hugot, M.H. Gandon, and J. Lépagnol. 1998a. Involvement of nicotinergic mechanisms in thyrotropin-releasing hormone-induced neurologic recovery after concussive head injury in the mouse. Eur. J. Pharmacol. 357: 163-171.
25. Lestage, P., C. Lebrun, F. Iop, A. Hugot, N. Rogez, P. Greve, D. Favale, M.H. Gandon, O. Rainbault, and J. Lépagnol. 1998b. S 17092-1, new post-proline cliving enzyme inhibitor: Memory enhancing effect and substance P neuromodulatory activity. In Behavioural Biology Advance . Progress in Alzheimer's and Parkinson's diseases, (ed. A. Fischer, I. Hanin, and M. Yoshida), pp. 653-660. Plenum Press, New York, NY.
26. Marighetto, A., N. Etchamendy, K. Touzani, C. Cortes-Torrea, B.K. Yee, J.N.P. Rawlins, and R. Jaffard. 1999. Knowing which and knowing what: A potential mouse model for age-related human declarative memory decline. Eur. J. Neurosci. 11: 3312-3322.
27. 1-11. Neuroscience 48: 595-605.
28. McDonald, R.J. and N.M. White. 1993. A triple dissociation of memory systems: hippocampus, amygdala and dorsal striatum. Behav. Neurosci. 107: 3-22.
29. Mellow, A.H., T.S. Sunderland, R.M. Cohen, B.A. Lawlor, L.J. Hill, P.A. Newhouse, M.R. Cohen, and D.L. Murphy. 1989. Acute effects of high-dose thyrotrophin-releasing hormone infusions in Alzheimer's disease. Psychopharmacol. 98: 403-407.
30. Mellow, A.H., S.M. Aronson, B. Giordani, and S. Berent. 1993. A peptide enhancement strategy in Alzheimer's disease; Pilot study with TRH/physostigmine infusions. Biol. Psychol. 34: 271-273.
31. Mohammed, A.H. 1993 Effects of cholinesterase inhibitors on learning and memory in rats: A brief review with special reference to THA. Acta. Neurol. Scand. 49: 29-35.
32. Molchan, S.E., A.H. Mellow, J.L. Hill, H.J. Weingartner, R.A. Martinez, B. Vitiello, and T. Sunderland. 1992. The effects of thyrotrophin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers. J. Psychopharmacol. 6:489-500.
33. Molchan, S.E., A.H. Mellow, B.A. Lawlor, H.J. Weingartner, R.M. Cohen, M.R. Cohen, and T. Sunderland. 1990. TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacol. 100: 84-89.
34. Pavone, F., F. Capone, M. Battaglia, and M. Sansone. 1998. Shuttle-box avoidance learning in mice: Improvement by combined glucose and tacrine. Neurobiol. Learn. Mem. 69: 204-210.
35. Pitsikas, N., B.M. Spruijt, M. Josephy, S. Algeri, and W.H. Gispen. 1991. Effect of ORG 2766, an ACTH(4-9) analogue, on recovery after bilateral transection of the fimbria fornix in the rat. Pharmacol. Biochem. Behav. 38: 931-934.
36. Poon, L.W. 1985. Differences in human memory with aging: Nature, causes, and clinical implications. In Handbook of the psychology of aging (ed. J.Birren and K.W. Schaie ), pp. 427-462. New York, NY.
37. Portevin, B., A. Benoist, G. Rémond, Y. Hervé, M. Vincent, J. Lépagnol, and G. Denanteuil. 1996. New prolyl endopeptidase inhibitors: in vitro and in vivo activities of azabicyclo[2.2.2]octane, azabicyclo[2.2.1]heptane, and perhytroindole derivatives. J. Med. Chem. 39: 2379-2391.
38. Qizilbash, N., A. Whitehead, J. Higgins, G. Wilcock, L. Schneider, and M. Farlow. 1998. Cholinesterase inhibition for Azheimer disease: A meta-analysis of the tacrine trials. Dementia trialists collaboration. JAMA 280: 1777-1782.
39. Riekkinen, P.J.R., J. Sirvio, M. Riekkinen, and P. Riekkinen. 1991. Effects of THA on passive avoidance retention performance of intact, nucleus basalis, frontal cortex and nucleus basaus + frontal cortex-lesioned rats. Pharmacol. Biochem. Behav. 39: 841-846.
40. Rossor, M.N., P.C. Emson, D. Dawbarn, C.Q. Mountjoy, and M. Roth. 1986. Neuropeptide and dementia. Progr. Brain Res. 66: 143-159.
41. Sarter, M. and J.P. Bruno. 1997. Cognitive functions of cortical acetylcholine: Towards a unifying hypothesis. Brain Res. Rev. 23: 28-46.
42. Schugens, M.M., I. Daum, M. Spindler, and N. Birbaumer. 1997. Differential effects of aging on explicit and implicit memory. Aging, Neuropsychology and Cognition 4: 33-44.
43. Wang, Z.P., S.Y. Man, and F. Tang. 1981. Age-related changes in the contents of neuropeptides in the brain and pituitary. Neurobiol. Aging 15: 529-534.
44. Whitty, C.J., G. Kapatos, and M.J. Bannon. 1993. Neurotrophic effects of substance P on hippocampal neurons in vitro. Neurosci. Lett. 164: 141-144.
45. Wilk, S. 1983. Minireview on prolyl endopeptidase. Life Sci. 33: 2149-2157.